Cannabis pharmaceuticals market seen reaching $85.68 billion by 2030

The Business Research Company says the global cannabis pharmaceuticals market is set to surge from $9.43 billion in 2025 to $85.68 billion by 2030, driven by wider medical use, clinical trials and more standardized cannabinoid products. North America led the market in 2025, while Asia-Pacific is projected to grow fastest.

Why it matters: - Cannabis-based prescription drugs are moving deeper into mainstream medical care as hospitals, regulators and drug developers expand their use. - The market’s projected growth signals rising demand for standardized cannabinoid therapies in areas like epilepsy, pain management, neurology and oncology.

What happened: - The Business Research Company released a cannabis pharmaceuticals market outlook projecting the sector will grow from $9.43 billion in 2025 to $14.74 billion in 2026. - The company projects the market will reach $85.68 billion by 2030. - The report is titled “Cannabis Pharmaceuticals Market Report 2026 – Market Size, Trends, And Global Forecast 2026-2035.” - The report says the market posted a 56.3% compound annual growth rate in the historical period and is forecast to grow at 55.3% through 2030. - A free sample is available here. - The full report is available here.

The details: - Cannabis pharmaceuticals are prescription medications made from cannabis-derived compounds and produced to clinical and regulatory standards. - The drugs use cannabinoids including tetrahydrocannabinol, or THC, and cannabidiol, or CBD. - The report says these medications are used to treat chronic pain, epilepsy and multiple sclerosis. - Growth in 2025 and 2026 was driven by broader recognition of cannabinoid therapy, more medical cannabis prescriptions, early cannabis-derived drugs, hospital pain management programs and regulatory approvals for specific cannabis medications. - Future growth is expected to be supported by investment in cannabis drug clinical trials, demand for standardized cannabinoid products, more use in neurological and oncology treatments, wider hospital adoption and more harmonized regulation. - The report highlights development of prescription-grade cannabis medicines, stronger clinical validation, expansion into neurological and pain-related disorders, regulated pharmaceutical pipelines and more precise dosing as major trends. - The report says the rising prevalence of epilepsy is a key market driver. - A World Health Organization report in February 2024 said about 50 million people worldwide were living with epilepsy. - The report says CBD can reduce seizure frequency and severity in patients who do not respond to conventional anti-epileptic medications.

Between the lines: - The forecast suggests cannabis drugs are shifting from niche products toward a more formal pharmaceutical category. - Strong growth assumptions also point to an industry still dependent on clearer regulation, clinical validation and broader physician acceptance. - The emphasis on standardized products and precision dosing shows the market is trying to move away from inconsistent consumer cannabis products.

What's next: - The Business Research Company expects continued growth as more cannabis-based drugs enter clinical development and more markets align their rules. - North America is expected to remain a major market after leading globally in 2025. - Asia-Pacific is projected to be the fastest-growing region during the forecast period. - The report covers Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa. - The company also added 2026 report features including market attractiveness scoring, TAM analysis, company scoring matrix graphics, Excel-based forecasting dashboards, market hotspots infographics and updated trend graphics.